Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries

Maturitas

Volumn 84, Issue , 2016, Pages 81-88

  Antoine, Caroline ^a   Ameye, Lieveke ^b   Paesmans, Marianne ^b   De Azambuja, Evandro ^b   Rozenberg, Serge ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Europe; Incidence; Menopause hormone therapy; Sales

Indexed keywords

TIBOLONE; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; AUSTRIA; BELGIUM; BREAST CANCER; BULGARIA; CANCER INCIDENCE; CANCER REGISTRY; CLINICAL ASSESSMENT; CYPRUS; CZECH REPUBLIC; DENMARK; DRUG MARKETING; ESTONIA; FEMALE; FINLAND; FOLLOW UP; GERMANY; HORMONAL THERAPY; HUMAN; ICELAND; IRELAND; MAJOR CLINICAL STUDY; MALTA; MENOPAUSAL HORMONE THERAPY; MENOPAUSE; NETHERLANDS; NORWAY; POLAND; SLOVAKIA; SLOVENIA; SWEDEN; SWITZERLAND; UNITED KINGDOM; AGED; BREAST NEOPLASMS; COMMERCIAL PHENOMENA; DRUG DATABASE; EUROPE; HORMONE SUBSTITUTION; INCIDENCE; MIDDLE AGED; UTILIZATION;

AGED; BREAST NEOPLASMS; COMMERCE; DATABASES, PHARMACEUTICAL; ESTROGEN RECEPTOR MODULATORS; EUROPE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; NORPREGNENES;

EID: 84952638546     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2015.11.010     Document Type: Article

References (54)

1. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, and et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
2. P.M. Ravdin, K.A. Cronin, N. Howlader, and et al. The decrease in breast-cancer incidence in 2003 in the United States N. Engl. J. Med. 356 2007 1670 1674
3. E. Hemminki, P. Kyyronen, and E. Pukkala Postmenopausal hormone drugs and breast and colon cancer: nordic countries 1995-2005 Maturitas 61 2008 299 304
4. M. Kumle Declining breast cancer incidence and decreased HRT use Lancet 372 2008 608 610
5. H.M. Verkooijen, V.C. Koot, G. Fioretta, and et al. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing wo European populations Breast Cancer Res. Treat. 107 February (3) 2008 389 395
6. K. Canfell, E. Banks, M. Clements, and et al. Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003 Breast Cancer Res. Treat. 117 October (3) 2009 671 673
7. A. Katalinic, A. Lemmer, A. Zawinell, R. Rawal, and A. Waldmann Trends in hormone therapy and breast cancer incidence - results from the German Network of Cancer Registries Pathobiology 76 2 2009 90 97
8. D.M. Parkin Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur. J. Cancer 45 2009 1649 1653
9. B. Seradour, H. Allemand, A. Weill, and P. Ricordeau Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006 Bull. Cancer 96 2009 E1 E6
10. M. Lambe, A. Wigertz, M. Holmqvist, and et al. Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years Breast Cancer Res. Treat. 121 June (3) 2010 679 683
11. A.Z. LaCroix, R.T. Chlebowski, J.E. Manson, WHI Investigators, and et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial JAMA 305 April (13) 2011 1305 1314
12. A. Fournier, F. Berrino, E. Riboli, V. Avenel, and F. Clavel-Chapelon Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort Int. J. Cancer 114 April (3) 2005 448 454
13. A. Fournier, S. Mesrine, M.C. Boutron-Ruault, and F. Clavel-Chapelon Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J. Clin. Oncol. 27 November (31) 2009 5138 5143
14. H. Lyytinen, E. Pukkala, and O. Ylikorkala Breast cancer risk in postmenopausal women using estradiol-progestogen therapy Obstet. Gynecol. 113 2009 65 73 360:573-587
15. C. Antoine, L. Ameye, M. Paesmans, and S. Rozenberg Systematic review about breast cancer incidence in relation to hormone replacement therapy use Climacteric 17 April (2) 2014 116 132
16. P.H. Zahl, B.H. Strand, and J. Maehlen Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study BMJ 328 April (7445) 2004 921 924
17. European Cancer Observatory, Cancer Screening, 2007 (http://eco.iarc.fr/).
18. N. Breen, K.A. Cronin, J.A. Tiro, H.I. Meissner, T.S. McNeel, S.A. Sabatino, F.K. Tangka, and S.H. Taplin Was the drop in mammography rates in 2005 associated with the drop in hormone therapy use? Cancer 117 December (24) 2011 5450 5460
19. C. Antoine, L. Ameye, M. Moreau, M. Paesmans, and S. Rozenberg Evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium Climacteric 14 August (4) 2011 464 471
20. Austria (www.statistik.at).
21. Belgium (www.kankerregister.be).
22. Denmark, Finland, Norway and Sweden (http://www-dep.iarc.fr/NORDCAN).
23. Germany (http://www.gekid.de/).
24. Ireland (http://www.ncri.ie/).
25. The Netherlands (http://www.cijfersoverkanker.nl/).
26. Switzerland (http://www.nicer.org).
27. England (http://www.ons.gov.uk).
28. Wales (http://www.wcisu.wales.nhs.uk/).
29. Scotland (http://www.isdscotland.org).
30. Northern Ireland (http://www.qub.ac.uk/research-centres/nicr/).
31. http://ec.europa.eu/eurostat/data/database
32. G. Verbeke, and G. Molenberghs Linear Mixed Models for Longitudinal Data. Springer Series in Statistics 2000 Springer-Verlag New-York
33. S.R. Cummings, B. Ettinger, P.D. Delmas, P. Kenemans, V. Stathopoulos, P. Verweij, M. Mol-Arts, L. Kloosterboer, L. Mosca, C. Christiansen, J. Bilezikian, E.M. Kerzberg, S. Johnson, J. Zanchetta, D.E. Grobbee, W. Seifert, R. Eastell, and LIFT Trial Investigators The effects of tibolone in older postmenopausal women N. Engl. J. Med. 359 August (7) 2008 697 708
34. Million Women Study Collaborators Breast cancer and hormone replacement therapy in the Million Women Study Lancet 362 2003 419 427
35. P. Kenemans, N.J. Bundred, J.M. Foidart, E. Kubista, B. von Schoultz, P. Sismondi, R. Vassilopoulou-Sellin, C.H. Yip, J. Egberts, M. Mol-Arts, R. Mulder, S. van Os, M.W. Beckmann, and LIBERATE Study Group Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial Lancet Oncol. 10 February (2) 2009 135 146
36. P. Suhrke, and P.H. Zahl Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study Cancer Med. 4 August (8) 2015 1303 1308
37. B. Michels Karin The rise and fall of breast cancer rates BMJ 344 2012 d8003
38. A. Gompel, and G. Plu-Bureau Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann. N.Y. Acad. Sci. 1205 September 2010 268 276
39. L. Esserman, Y. Shieh, and I. Thompson Rethinking screening for breast cancer and prostate cancer JAMA 302 October (15) 2009 1685 1692
40. Programme de Dépistage du Cancer du Sein. Comparaison des trois premiers tours 2002-2003, 2004-2005 et 2006-2007. Rapport numéro 7 de l'Agence Intermutualiste.
41. Eurostat report, http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/.
42. R.L. Prentice, Y. Huang, D.A. Hinds, and et al. Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer Cancer Epidemiol. Biomarkers Prev. 18 November (11) 2009 3079 3085
43. G. Ena, and S. Rozenberg Issues to debate on the Women's Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study Hum. Reprod. 18 November (11) 2003 2245 2248
44. K.J. Buhling, F.S. von Studnitz, A. Jantke, C. Eulenburg, and A.O. Mueck Attitude of German gynecologists towards prescribing HRT before and after the WHI study Climacteric 15 August (4) 2012 326 331 10.3109/13697137.2011.631061 (Epub 2011 Dec 27)
45. S. Rozenberg, C. Fellemans, M. Kroll, and J. Vandromme The menopause in Europe Int. J. Fertil. Womens Med. 45 March-April (2) 2000 182 189 (Review. Erratum in: Int. J. Fertil. Womens Med. 45 (July-August(4)) (2000) 296)
46. C.H. Ahern, Y. Cheng, and Y. Shen Risk-specific optimal cancer screening schedules: an application to breast cancer early detection Stat. Biosci. 3 December (2) 2011 169 186
47. C. Schneider, S.S. Jick, and C.R. Meier Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations Climacteric 12 December (6) 2009 514 524
48. C. Bouchardy, M. Usel, H.M. Verkooijen, and et al. Changing pattern of age-specific breast cancer incidence in the Swiss canton of Geneva Breast Cancer Res. Treat. 120 April (2) 2010 519 523
49. K.H. Sharpe, P. McClements, D.I. Clark, J. Collins, A. Springbett, and D.H. Brewster Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy Eur. J. Cancer 46 March (5) 2010 937 943
50. S. Lee, A.C. Shafe, and M.R. Cowie UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database BMJ Open 1 January (2) 2011 e000269
51. M. Hiligsmann, O. Bruyère, D. Roberfroid, C. Dubois, Y. Parmentier, J. Carton, J. Detilleux, P. Gillet, and J.Y. Reginster Trends in hip fracture incidence and in the prescription of anti-osteoporosis medications during same time period in Belgium (2000-2007) Arthritis Care Res. (Hoboken) January 2012 10.1002/acr.21607 (Epub ahead of print)
52. N.K. Mehta, and V.W. Chang Secular declines in the association between obesity and mortality in the United States Popul. Dev. Rev. 37 September (3) 2011 435 451
53. R.T. Chlebowski, L.H. Kuller, R.L. Prentice, M.L. Stefanick, J.E. Manson, M. Gass, A.K. Aragaki, J.K. Ockene, D.S. Lane, G.E. Sarto, A. Rajkovic, R. Schenken, S.L. Hendrix, P.M. Ravdin, T.E. Rohan, S. Yasmeen, G. Anderson, and WHI Investigators Breast cancer after use of estrogen plus progestin in postmenopausal women N. Engl. J. Med. 360 February (6) 2009 573 587 10.1056/nejmoa0807684
54. A. Fournier, S. Mesrine, L. Dossus, M.C. Boutron-Ruault, F. Clavel-Chapelon, and N. Chabbert-Buffet Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort Breast Cancer Res. Treat. 145 June (2) 2014 535 543 10.1007/s10549-014-2934-6 (Epub 2014 Apr 30)